Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
- |
Employees |
862 |
Revenues (TTM) (Millions $) |
94 |
Net Income (TTM) (Millions $) |
-118 |
Cash Flow (TTM) (Millions $) |
93 |
Capital Exp. (TTM) (Millions $) |
10 |
Genetron Holdings Ltd
Genetron Holdings Ltd is a cutting-edge biotech company that develops and manufactures advanced gene testing and diagnostic solutions for cancer and other diseases. It was founded in 2015 and its headquarters are located in Beijing, China. Genetron Holdings Ltd is known for its innovative and advanced technology that enables it to provide reliable diagnostic and data analysis solutions to the medical industry.
Genetron's services and products have been widely used by hospitals, clinical labs, and research institutions across China and other countries. Its core business segments are cancer diagnosis and treatment, genetic screening and testing, and big data analysis. Its products are designed to help doctors and researchers better understand complex genetic and biological data to improve the accuracy of cancer diagnoses and provide personalized treatment plans for patients.
Using state-of-the-art technology, such as next-generation sequencing (NGS), Genetron's products are able to analyze cancer-related genes and genetic mutations with a high level of accuracy. The company's products also utilize artificial intelligence and machine learning algorithms to analyze large volumes of medical data quickly and accurately. This enables doctors to diagnose cancer at earlier stages, determine the most effective treatments, and monitor the efficacy of therapies.
Genetron Holdings Ltd has an experienced team of professionals, including biologists, bioinformatics experts, and data analysts who work together to advance its mission of advancing precision medicine for cancer and other diseases. The company has also established good relationships with major medical institutions and academic research centers across China and the world.
In conclusion, Genetron Holdings Ltd is a leader in the field of precision medicine and innovative technology that is transforming cancer diagnosis and treatment. Its focus on precision medicine is helping to revolutionize the way cancer is diagnosed and treated, leading to more accurate diagnoses, improved personalized treatment plans, and better outcomes for patients.
Company Address: 1-2/F, Building 11, Zone 1 Beijing 102206
Company Phone Number: 5090-7500 Stock Exchange / Ticker: NASDAQ GTH
GTH is expected to report next financial results on May 11, 2024. |
|
|